This early-stage trial tests a new nitric oxide mist (RESP30X) in 60 adults with non-cystic fibrosis bronchiectasis who have chronic lung infections. The main goals are to check safety and how well the body tolerates the treatment, while also seeing if it can reduce bacteria in t…
Phase: PHASE1, PHASE2 • Sponsor: Thirty Respiratory Limited • Aim: Disease control
Last updated May 08, 2026 12:02 UTC